Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.5K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.5K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

843
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
843
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Chronic obstructive pulmonary disease: diagnosis, monitoring and chronic management in nursing practice.

British journal of nursing (Mark Allen Publishing)·2026
Same author

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.

Cell reports. Medicine·2026
Same author

The path forward for T cell engagers in patients with prostate cancer.

Journal for immunotherapy of cancer·2026
Same author

Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling study.

Journal of medical economics·2026
Same author

Implementation of a Multihospital Electronic Medical Record-Based Insulin Order Set to Reduce Hypoglycemic Events.

AACE endocrinology and diabetes·2025
Same author

Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

International journal of radiation oncology, biology, physics·2025
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

前立腺がんは前立腺がんである.

Gerhardt Attard1, Chris Parker2, Ros A Eeles3

  • 1Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

Lancet (London, England)
|June 16, 2015
PubMed
まとめ
この要約は機械生成です。

最近の前立腺がんの研究は,標的型スクリーニングのための遺伝的理解を進めており,個別化された治療のための分子サブタイプを特定しています. 転移性疾患の生存率は改善しているが,新しい治療法の最適な配列化はさらなる研究を必要としている.

さらに関連する動画

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K

関連する実験動画

Last Updated: Apr 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K

科学分野:

  • 腫瘍学 腫瘍学
  • 遺伝学 遺伝学とは
  • トランスレーションアル・リサーチ

背景:

  • 前立腺がんの研究は,過去10年間で著しく進歩しました.
  • 高リスク変異 (例えばBRCA2,HOXB13) と一般的な低リスクアレルを含む,家族性前立腺がんの遺伝的基礎のより深い理解は,リスクのある個人を特定するのに役立ちます.
  • 現在,前立腺特異抗原 (PSA) を用いた前立腺癌のスクリーニングは,死亡率を下げているにもかかわらず,過度の診断と不必要な生検のため,論争の的となっている.

研究 の 目的:

  • 前立腺がんの研究における最近の進展をレビューし,遺伝学的な発見,分子サブタイプ化,治療の進歩に焦点を当てます.
  • 局所性および転移性前立腺がん,特にカストレーション耐性前立腺がん (CRPC) の管理における課題を強調する.
  • 前立腺がんの管理をパーソナライズするために,さらなる臨床的および翻訳的研究の緊急性を強調する.

主な方法:

  • 前立腺がんの研究における最新の科学文献と臨床試験データのレビュー.
  • ゲノム・ワイド・アソシエーション・スタディ (GWAS) とファミリアル・ミューテーション・識別を含む遺伝学的発見の分析.
  • CRPC治療を含む局所性および転移性前立腺がんの治療戦略の評価.

主要な成果:

  • 標的スクリーニングのための重要な遺伝子変異 (例えば,BRCA2,HOXB13) と一般的なアレルの識別.
  • 前立腺がんを分子サブタイプ (例えば,ETS遺伝子融合陽性,SPINK1過剰発現,CHD1損失) に分類して,潜在的な患者層格化を図る.
  • 転移性カストレーション耐性前立腺がん (mCRPC) の生存率が大幅に改善され,ドセタキセルに加えて5つの新薬が登場しました.

結論:

  • 遺伝学と分子サブタイプ化の進歩により,よりパーソナライズされた前立腺がんのスクリーニングと管理の可能性が生まれています.
  • mCRPCの生存率は改善しているが,信頼性の高いデータと高い薬剤コストの欠如により,最適な治療法の選択と配列は依然として困難である.
  • 継続的な臨床的および翻訳的研究は,前立腺がんの治療を改善し,パーソナライズするために不可欠です.